替吉奥联合奈达铂治疗晚期食管癌近期疗效观察  

Observation of S-1 capsule combined with nedaplatin in treating advanced esophageal cancer

作　　者：成美英[1] 偰燕燕[1] 

机构地区：[1]江苏大学附属人民医院肿瘤科,镇江212000

出　　处：《齐齐哈尔医学院学报》2013年第2期188-189,共2页Journal of Qiqihar Medical University

摘　　要：目的观察替吉奥联合奈达铂治疗晚期食管癌近期疗效及毒副反应。方法 25例晚期食管癌均接受化疗,替吉奥80 mg/(m2.d),分2次,餐后口服,1～14 d;奈达铂80 mg/m2,1 d,静脉滴注1 h以上。21 d为一个周期,2个周期后行胸腹部CT及消化道钡餐造影或胃镜评价疗效,并评价毒副作用。结果 25例患者均可评价疗效,完全缓解(CR)0例,部分缓解(PR)10例,病情稳定(SD)6例,病情进展(PD)9例,有效率(CR+PR)为40%,临床获益率(CR+PR+SD)为64%。中位疾病进展时间5.1个月,1年生存率68%。主要毒副反应为血液学毒性、消化道反应、肝功能损伤、皮疹、耳神经毒性、脱发等。结论替吉奥联合奈达铂治疗晚期食管癌疗效较好,毒副反应可耐受。Objective To evaluate the efficiency and toxicities of S-1 capsule combined with nedaplatin in the treatment of advanced esophageal cancer. Methods Twenty-five patients with advanced esophageal cancer received the chemotherapy： S-1 capsule 80 rag/m：, twice daily for 14 days; nedaplatin 80 mg/m2 one day, the chemotherapy was repeated every 21 days. After 2 cycles of chemotherapy, the efficiency was evaluated. Results All of the 25 cases could be evaluated, the overall response rate was 40.0%, the disease control rate was 64.0%, the median survival time was 5.1 months. The major toxicities were myeloid suppression. Conclusions S-1 capsule combined with nedaplatin is effect and safe in the treatment of advanced esophageal cancer.

关 键 词：替吉奥 奈达铂 食管癌 化疗 

分 类 号：R735.1[医药卫生—肿瘤]